BiotechTV - News | Écouter podcast en ligne gratuitement

488 épisodes

Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1
15/10/2026 | 11 min
CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.
At Dana-Farber Cancer Institute in Boston, President & CEO Ben Ebert and Professor and Investigator Cigall Kadoch discuss the latest trends in cancer research
14/10/2026 | 19 min
They discuss recent advances, what's ahead, Cigall's work in epigenetics, and how a new hospital will be purpose built for patients with the best new technologies in clinical research.
Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more
07/10/2026 | 23 min
From the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in Alzheimer's, and how he plans to invest for the future.
After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress
05/10/2026 | 27 min
He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.
Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
02/10/2026 | 20 min
CEO Markus Warmuth walks us through the data and provides a broader update on the pipeline progress at Monte Rosa and for the field of degraders and molecular glues more broadly.